MK0767 and Sulfonylurea Combination Study (0767-027)

• Status: Terminated
• Trial end date: 2003-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess MK0767's ability vs. placebo to control blood glucose in patients with type 2 diabetes and to gauge whether fasting blood glucose is lowered, blood fats are improved, and insulin levels are impacted.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Type 2 Diabetes with inadequate glycemic control

• On Sulfonylurea monotherapy

• Male or non-pregnant Females

• Age 21 to 78 years, inclusive

• On a stable dose of sulfonylurea for at least 2 weeks prior to Visit 2/Week-6

Exclusion Criteria:

• History of Type 1 diabetes

• Patient is currently on insulin (monotherapy or in combination with oral agent), Rosiglitazone or pioglitazone or other PPAR-y agonists, Metformin agents

• Patients with history of or intolerance of PPAR-y agonists